{"nctId":"NCT02721641","briefTitle":"A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer","startDateStruct":{"date":"1999-06"},"conditions":["Neoplasms"],"count":69,"armGroups":[{"label":"Herceptin","type":"EXPERIMENTAL","interventionNames":["Drug: Herceptin"]}],"interventions":[{"name":"Herceptin","otherNames":["Trastuzumab"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ongoing participants from any completed global Roche-sponsored Herceptin trial\n* Participants enrolled in any Roche-sponsored Herceptin trial who have at least stable disease (or whose disease has not recurred) during Herceptin therapy at the end of the lead-in trial\n* Available study termination data (including tumor assessment and laboratory data) on the Case Report Form for the lead-in trial\n* Judged eligible by the investigator following a thorough risk/benefit assessment, if signs of chronic heart failure developed during the lead-in trial\n\nExclusion Criteria:\n\n* Pregnant or nursing women\n* Women of childbearing potential unless using effective contraception as determined by the investigator\n* Severe dyspnea at rest requiring supplementary oxygen therapy\n* Severe uncontrolled systemic disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"On-Study Duration of Trial Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"386.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Drop in Left Ventricular Ejection Fraction (LVEF) Below 45 Percent (%)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Withdrawn From Study Because of LVEF Dysfunction","description":"LVEF dysfunction was defined as low LVEF measured on two consecutive assessments, with the second assessment performed after 3 weeks of study medication being withheld. Low LVEF included values less than or equal to 39% or values between 40% and 45% (inclusive) with a decrease of 10 or more percentage points from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":69},"commonTop":[]}}}